173 related articles for article (PubMed ID: 31897259)
21. Pharmacist-Managed Refill Service Impacts on Clinician Workload and Medication Interventions in a Federally Qualified Health Center.
Hurley-Kim K; Keyvani A; Ahmed R; Wong HW; McBane S
J Prim Care Community Health; 2023; 14():21501319231168716. PubMed ID: 37070677
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of a Conservative Pharmacist-led U-500R Insulin Management Protocol in the Primary Care Setting.
Dumont C; Fitzgerald L; Valdez CA
J Prim Care Community Health; 2020; 11():2150132720973827. PubMed ID: 33218271
[TBL] [Abstract][Full Text] [Related]
23. Pharmacist collaborative management of poorly controlled diabetes mellitus: a randomized controlled trial.
Jameson JP; Baty PJ
Am J Manag Care; 2010 Apr; 16(4):250-5. PubMed ID: 20394460
[TBL] [Abstract][Full Text] [Related]
24. Provider survey of the roles of clinical pharmacists in primary care in a Federally Qualified Health Center versus an Accountable Care Organization.
Amin P; Jones S; Selby C; McCarty J; Smith F; Douglass G
Explor Res Clin Soc Pharm; 2023 Mar; 9():100242. PubMed ID: 37008897
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of pharmacist consults within a collaborative enhanced primary care team model to improve diabetes care.
Firkus D; McCoy RG; Matulis J; Kessler M; Mara K; Herges J
PLoS One; 2023; 18(1):e0280654. PubMed ID: 36662741
[TBL] [Abstract][Full Text] [Related]
26. Pharmacist-led telehealth disease management program for patients with diabetes and depression.
Cohen LB; Taveira TH; Wu WC; Pirraglia PA
J Telemed Telecare; 2020 Jun; 26(5):294-302. PubMed ID: 30691328
[TBL] [Abstract][Full Text] [Related]
27. Impact of pharmacist-managed erythropoiesis-stimulating agents clinics for patients with non-dialysis-dependent CKD.
Aspinall SL; Cunningham FE; Zhao X; Boresi JS; Tonnu-Mihara IQ; Smith KJ; Stone RA; Good CB;
Am J Kidney Dis; 2012 Sep; 60(3):371-9. PubMed ID: 22633556
[TBL] [Abstract][Full Text] [Related]
28. Pharmacists improve diabetes outcomes: a randomized controlled trial.
Wagner ML; McCarthy C; Bateman MT; Simmons D; Prioli KM
J Am Pharm Assoc (2003); 2022; 62(3):775-782.e3. PubMed ID: 35027281
[TBL] [Abstract][Full Text] [Related]
29. Design of the POINT study: Pharmacotherapy Optimisation through Integration of a Non-dispensing pharmacist in a primary care Team (POINT).
Hazen AC; Sloeserwij VM; Zwart DL; de Bont AA; Bouvy ML; de Gier JJ; de Wit NJ; Leendertse AJ
BMC Fam Pract; 2015 Jul; 16():76. PubMed ID: 26135582
[TBL] [Abstract][Full Text] [Related]
30. Impact of pharmacist-involved collaborative care on diabetes management in a primary healthcare setting using real-world data.
Abdulrhim S; Awaisu A; Ibrahim MIM; Diab MI; Hussain MAM; Al Raey H; Ismail MT; Sankaralingam S
Int J Clin Pharm; 2022 Feb; 44(1):153-162. PubMed ID: 34637104
[TBL] [Abstract][Full Text] [Related]
31. Health care provider management of patients with type 2 diabetes mellitus: analysis of trends in attitudes and practices.
Williamson C; Glauser TA; Burton BS; Schneider D; Dubois AM; Patel D
Postgrad Med; 2014 May; 126(3):145-60. PubMed ID: 24918800
[TBL] [Abstract][Full Text] [Related]
32. Implementation of a pharmacist-run telephonic insulin titration service.
Weidman-Evans E; Evans J; Eastwood R; Fort A
J Am Pharm Assoc (2003); 2012; 52(6):e266-72. PubMed ID: 23229989
[TBL] [Abstract][Full Text] [Related]
33. Using pharmacists to improve risk stratification and management of stage 3A chronic kidney disease: a feasibility study.
Chang AR; Evans M; Yule C; Bohn L; Young A; Lewis M; Graboski E; Gerdy B; Ehmann W; Brady J; Lawrence L; Antunes N; Green J; Snyder S; Kirchner HL; Grams M; Perkins R
BMC Nephrol; 2016 Nov; 17(1):168. PubMed ID: 27825313
[TBL] [Abstract][Full Text] [Related]
34. Measurement of Pharmacist-Physician Collaborative Care on Therapeutic Inertia in Patients With Type 2 Diabetes.
Cowart K; Emechebe N; Pathak R; Abbruzese L; Hann J; Lloyd A; Roetzheim R; Zgibor J; Updike WH
Ann Pharmacother; 2022 Feb; 56(2):155-161. PubMed ID: 34105397
[TBL] [Abstract][Full Text] [Related]
35. Impact of clinical pharmacist collaboration in patients beginning insulin pump therapy: a retrospective and cross-sectional analysis.
Ledford JL; Hess R; Johnson FP
J Drug Assess; 2013; 2(1):81-6. PubMed ID: 27536441
[TBL] [Abstract][Full Text] [Related]
36. The effectiveness of continuous subcutaneous insulin pumps with continuous glucose monitoring in outpatient adolescents with type 1 diabetes: A systematic review.
Matsuda E; Brennan P
JBI Libr Syst Rev; 2012; 10(42 Suppl):1-10. PubMed ID: 27820140
[TBL] [Abstract][Full Text] [Related]
37. Charitable Pharmacies as Catalysts for Coordinated Care: Pharmacist Management of Blood Glucose Among Under-Resourced Patients With Type 2 Diabetes.
Langhinrichsen-Rohling J; Richie F; Kelley M; Selwyn C; Archer S; Blejwas E
Health Promot Pract; 2024 Mar; 25(2):254-262. PubMed ID: 36627769
[TBL] [Abstract][Full Text] [Related]
38. Economic analysis of insulin initiation by pharmacists in a Canadian setting: The RxING study.
Brown S; Al Hamarneh YN; Tsuyuki RT; Nehme K; Sauriol L
Can Pharm J (Ott); 2016 May; 149(3):130-7. PubMed ID: 27212963
[TBL] [Abstract][Full Text] [Related]
39. Quality of care of a pharmacist-managed diabetes service compared to usual care in an indigent clinic.
Irons BK; Seifert CF; Horton NA
Diabetes Technol Ther; 2008 Jun; 10(3):220-6. PubMed ID: 18473697
[TBL] [Abstract][Full Text] [Related]
40. Changes in clinical markers observed from pharmacist-managed cardiovascular risk reduction clinics in federally qualified health centers: A retrospective cohort study.
Gonzalvo JD; Meredith AH; Pastakia SD; Peters M; Eberle M; Schmelz AN; Pence L; Triboletti JS; Walroth TA
PLoS One; 2023; 18(3):e0282940. PubMed ID: 36920963
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
